Regulatory 2024-08-15 | Half-Year Report 2024: Orviglance Completes Clinical Development with Successful Phase 3 Study PDF Report Presentation Webcast
Regulatory 2024-04-08 | Annual Report 2023: Solid Progress with Orviglance Phase 3 Patient Recruitment Completed and Headline Results Expected by May 2024 PDF Report Presentation Webcast
Regulatory 2023-08-18 | Half-Year report 2023: Re-evaluation required after intra-reader inconsistency in scoring of images from phase 3 study SPARKLE PDF Report Presentation Webcast
Regulatory 2023-04-13 | Correction: Ascelia Pharma publishes annual report for 2022 PDF Report Presentation Webcast
Regulatory 2023-04-13 | Ascelia Pharma publishes annual report for 2022 PDF Report Presentation Webcast
Regulatory 2022-08-18 | Half-year report 2022: Strong results from Orviglance Food Effect Study PDF Report Presentation Webcast
Regulatory 2022-04-11 | Ascelia Pharma publishes Annual Report for 2021 PDF Report Presentation Webcast
Regulatory 2021-08-19 | Quarterly Report Q2 2021: Preparing Oncoral for the next level PDF Report Presentation Webcast
Regulatory 2021-03-30 | Ascelia Pharma publishes Annual Report for 2020 PDF Report Presentation Webcast
Regulatory 2021-03-17 | Ascelia Pharma has carried out a directed new share issue raising SEK 200 million PDF Report Presentation Webcast
Regulatory 2021-03-17 | Ascelia Pharma intends to carry out a directed new share issue PDF Report Presentation Webcast
Regulatory 2020-08-20 | Quarterly Report Q2-2020: First participant in the hepatic study PDF Report Presentation Webcast
Regulatory 2020-04-06 | Ascelia Pharma publishes Annual Report for the financial year 2019 PDF Report Presentation Webcast
Regulatory 2019-10-14 | Ascelia Pharma publishes Annual Report for the financial year 2018/2019 PDF Report Presentation Webcast
